The table below summarizes key differences between low-grade astrocytoma (Grade II), anaplastic astrocytoma (Grade III), and glioblastoma (Grade IV) – including how fast they grow, what they look like under the microscope, common molecular markers, typical treatments, and prognosis.
| Feature |
Grade II Astrocytoma“Low-Grade” (Diffuse Astrocytoma) |
Grade III Astrocytoma“Anaplastic Astrocytoma” |
Grade IV Astrocytoma“Glioblastoma” (GBM) |
| WHO Grade |
II (Low-grade) |
|
IV (High-grade, most aggressive) |
| Growth Rate |
Slower-growing (often takes years to progress) |
Faster growth; more aggressive than Grade II |
Very rapid growth and spread |
| Cellularity (cell density) |
Low–moderate (cells slightly increased in number) |
High (more crowded tumor cells than Grade II) |
Very high (densely packed abnormal cells) |
| Mitotic Activity (cell division) |
Low (few cells actively dividing) |
High (frequent cell divisions seen) |
Very high (many cells dividing uncontrollably) |
| Necrosis (dead tissue in tumor) |
None (no dead areas present) |
None (necrosis is not seen in Grade III) |
Yes – contains areas of necrosis (dead cells) |
| IDH Status (IDH gene mutation) |
IDH-mutant in most cases (common in lower-grade) |
IDH-mutant (usually; defines it as astrocytoma) |
IDH-wildtype in ~90% of cases (the “classic” GBM)Note: IDH-mutant grade IV tumors exist but are often called “astrocytoma, IDH-mutant, grade 4.” |
| MGMT Promoter Methylation (DNA marker influencing chemo response) |
Sometimes present (not always tested at Grade II; methylation, if present, may predict better response to chemo) |
Sometimes present (often tested; if methylated, tumor responds better to chemotherapy) |
Often present in a subset (~40% of GBMs); routinely tested – methylation predicts better response to temozolomide chemo |
| Typical Treatment |
Surgery to remove as much as possible. If tumor cannot be fully resected or shows growth, radiation and/or chemotherapy are considered. In some cases (small, asymptomatic tumors) doctors may initially observe with regular MRI scans (“watch and wait”). |
Surgery followed by radiation + chemotherapy is standard (high-grade regimen). Temozolomide (chemo pill) is often used after surgery along with radiation. Clinical trials may be considered. |
Aggressive multimodal therapy: Maximal safe surgery, This is followed by a combination of radiation and chemotherapy, known as the Stupp protocol. After that, patients often continue chemotherapy for at least six months. Some may also use a wearable device called Tumor Treating Fields, which helps slow down tumor regrowth. Depending on the individual case, clinical trials or targeted therapies may also be offered. |
| Prognosis (outlook) |
Median survival* ~8–10 years with treatment. Many patients live longer, especially if IDH-mutant. (Cases with favorable genetics can sometimes survive 15+ years.) |
Median survival* ~3–5 years with current treatments. An IDH mutation and younger age generally improve outcomes. Long-term survival beyond 5 years is possible in some cases (especially if tumor responds well to therapy). |
Median survival* ~15 months (1.3 years) despite intensive treatment. However, about 25% of GBM patients live ~2 years or more, particularly if the tumor has favorable markers like MGMT methylation. Only a small percentage (single-digits) survive 5+ years. (Research is ongoing to improve this.) |
Note: Grade I (Pilocytic Astrocytoma) is not included in the table because it’s a special case. Grade I tumors are typically non-malignant, slow growing, and often occur in children. They can often be cured by surgery alone, with a 5-year survival rate around 95% or higher. Grade I astrocytomas rarely “upgrade” to higher grades and are much less aggressive than the diffuse astrocytomas discussed above.
As the table shows, higher grade = more aggressive behavior, and usually more intensive treatment.
* Median survival refers to the time at which half the patients are still alive, and half have passed away after diagnosis or treatment. So if the median survival is 15 months, it means that 50% of patients live longer than 15 months, and 50% live less. It’s not the average or the maximum—it’s the middle point of all outcomes.
Why Does Grade Matter for Treatment and Decisions?
When planning treatment, doctors pay close attention to your tumor’s grade (and molecular markers) because it guides how aggressive the therapy should be. Here are some practical implications:
- Treatment Urgency and Intensity: If you have a GBM (Grade IV), your medical team will recommend starting treatment immediately after diagnosis. This typically means surgery as soon as possible, followed by combined radiation and chemotherapy. High-grade tumors like Grade III and IV are considered brain cancers – delaying therapy could risk the tumor growing or spreading. In contrast, with a lower-grade (Grade II) astrocytoma that isn’t causing major symptoms, your doctor might consider a short period of observation after surgery. For example, some small Grade II tumors can be monitored with regular MRIs (“watch and wait”) rather than jumping into radiation right away. This is because the tumor is slow-growing and the risks of treatment side effects might outweigh immediate benefit if you’re currently well. In general, the lower the grade, the more cautious and personalized the approach – the higher the grade, the more aggressive and urgent the treatment.
- Surgery Extent: Surgery is usually the first step for any astrocytoma if safely feasible, to confirm the diagnosis and remove tumor. For high grades, neurosurgeons aim to remove as much tumor as possible because that has been shown to prolong survival (especially in GBM, where removing ≥90% of the tumor can improve outcomes). In lower-grade tumors, complete removal can sometimes even be curative or delay the need for further treatments. With Grade II, if a surgeon achieves a gross-total resection and the tumor has good markers, they may hold off on radiation/chemo and just watch. With Grade III and IV, even if surgery goes well, additional therapy is nearly always needed because microscopic cells are left behind that can regrow.
- Radiation and Chemotherapy: For Grade III and IV astrocytomas, standard care includes both radiation therapy and chemotherapy after surgery. For Grade IV GBM, the established regimen is 6 weeks of daily radiation combined with daily temozolomide (an oral chemotherapy), followed by monthly cycles of temozolomide – this is often called the Stupp protocol. Grade III tumors are often treated similarly (radiation plus chemo, although sometimes the chemo drug or schedule may differ). For Grade II, treatment varies: some patients receive radiation and/or chemotherapy (especially younger patients or those with subtotally resected tumors), while others are observed until there’s evidence of tumor growth. Clinical trials have shown that adding chemotherapy (like a combo called PCV or temozolomide) to radiation can improve survival in lower-grade gliomas, particularly if they have certain genetic features. Your oncologist will tailor this based on your case.
- Molecular Markers Guiding Therapy: Modern neuro-oncology is personalized. IDH-mutant tumors (grades II–III) might prompt different discussions – for example, there are emerging targeted drugs (IDH inhibitors) being tested that specifically attack IDH-mutant tumor cells. In fact, a recent clinical trial showed an IDH inhibitor called vorasidenib can significantly delay tumor growth in IDH-mutant low-grade gliomas. This is very hopeful news for patients with IDH-mutant astrocytomas, as of 2025. MGMT promoter methylation, especially relevant in GBM, can influence decisions too. If a GBM tumor is unmethylated (meaning the MGMT gene is active), doctors know that standard chemo is less effective. In an older patient with an unmethylated GBM, for instance, the care team might opt for radiation therapy alone or an alternative approach, since temozolomide chemo may not add much benefit in that scenario. On the other hand, a methylated MGMT status strongly suggests the patient will benefit from temozolomide, so chemo is definitely recommended. In summary, these molecular details help fine-tune your treatment plan – a hallmark of modern “precision medicine.”
- Prognosis and Life Planning: Knowing the grade gives a general idea of outlook, which helps in making personal plans and decisions. For example, a lower-grade tumor patient might be looking at many years of managing a slow disease (often continuing normal life with periodic treatment), whereas a GBM patient faces an acutely serious disease where median survival is about 12–18 months. This influences how aggressively one pursues experimental treatments, how one arranges family or work matters, etc. Importantly, remember that statistics like median survival are just numbers – they don’t determine any individual’s fate. There are GBM patients who live 3, 5, even 10+ years, and conversely, lower-grade tumor patients who have unpredictable courses. Your healthcare team can put your specific prognosis in context, considering factors like your age, overall health, tumor genetics, and response to therapy. No matter the grade, there is always hope and new research happening. High-grade tumors have many clinical trials underway (from immunotherapy to gene therapies), and low-grade tumors have novel targeted drugs on the horizon (e.g. IDH inhibitors as mentioned). This means the outlook is steadily improving.
Sources: This guide is based on current medical literature and patient education resources (updated 2025), including expert input from MD Anderson Cancer Center, the American Association of Neurological Surgeons, and recent research findings in oncology. All medical information has been reviewed for accuracy and is intended for educational purposes. Always consult your physician for advice tailored to your situation. Stay hopeful and informed – science is making strides against astrocytomas and glioblastomas every day.
Find Advanced Treatment on our Website under Study Finder
Download the Wetrials App to learn more.
